← FDA DRUG APPROVALS

FDA ANDA · ANDA077139

CARBOPLATIN

Sponsor: TEVA PHARMS USA

APPLICATION
ANDA077139
TYPE
ANDA
ORIGINAL APPROVAL
2005-09-21
LATEST ACTION
2012-03-14
ROUTE
INTRAVENOUS
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

CARBOPLATINDiscontinued
CARBOPLATIN 600MG/60ML (10MG/ML) · INJECTABLE · INTRAVENOUS
CARBOPLATINDiscontinued
CARBOPLATIN 150MG/15ML (10MG/ML) · INJECTABLE · INTRAVENOUS
CARBOPLATINDiscontinued
CARBOPLATIN 450MG/45ML (10MG/ML) · INJECTABLE · INTRAVENOUS
CARBOPLATINDiscontinued
CARBOPLATIN 50MG/5ML (10MG/ML) · INJECTABLE · INTRAVENOUS

Approval history

2012-03-14Labeling · Supplement 16LetterAP
2011-06-06Manufacturing (CMC) · Supplement 6AP
2005-09-21OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →